{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T07:06:52Z","timestamp":1790233612677,"version":"4.1.0"},"reference-count":213,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000028","name":"Institute of Circulatory and Respiratory Health","doi-asserted-by":"crossref","award":["Grant 37977, First Pilot Foundation Grant 143348 and Project Grant PJT 186248, a Canada Research Chair."],"award-info":[{"award-number":["Grant 37977, First Pilot Foundation Grant 143348 and Project Grant PJT 186248, a Canada Research Chair."]}],"id":[{"id":"10.13039\/501100000028","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008582","name":"McGill University","doi-asserted-by":"crossref","award":["Canada Research Chair"],"award-info":[{"award-number":["Canada Research Chair"]}],"id":[{"id":"10.13039\/100008582","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"crossref","award":["37917"],"award-info":[{"award-number":["37917"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"crossref","award":["First Pilot Foundation Grant 143348"],"award-info":[{"award-number":["First Pilot Foundation Grant 143348"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"crossref","award":["Project Grant PJT 186248"],"award-info":[{"award-number":["Project Grant PJT 186248"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000028","name":"Institute of Circulatory and Respiratory Health","doi-asserted-by":"crossref","award":["Grant 37977, First Pilot Foundation Grant 143348 and Project Grant PJT 186248, a Canada Research Chair."],"award-info":[{"award-number":["Grant 37977, First Pilot Foundation Grant 143348 and Project Grant PJT 186248, a Canada Research Chair."]}],"id":[{"id":"10.13039\/501100000028","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008582","name":"McGill University","doi-asserted-by":"crossref","award":["Canada Research Chair"],"award-info":[{"award-number":["Canada Research Chair"]}],"id":[{"id":"10.13039\/100008582","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"crossref","award":["37917"],"award-info":[{"award-number":["37917"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"crossref","award":["First Pilot Foundation Grant 143348"],"award-info":[{"award-number":["First Pilot Foundation Grant 143348"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"crossref","award":["Project Grant PJT 186248"],"award-info":[{"award-number":["Project Grant PJT 186248"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Kidney360"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:p>\n                    Aldosterone, produced by adrenal glomerulosa cells, stimulated by angiotensin II, adrenocorticotrophin, and potassium, and inhibited by natriuretic peptides, plays a role in hypertension and CKD development and progression. Its effects are mediated by nuclear mineralocorticoid receptors inducing genomic effects and putatively by a membrane G-protein\u2013coupled receptor which could be the G-protein\u2013coupled estrogen receptor, triggering nongenomic actions. The classical effect of aldosterone is on the distal nephron to retain Na\n                    <jats:sup>+<\/jats:sup>\n                    and water and excrete potassium, contributing to electrolyte and extracellular volume control. However, aldosterone also acts by stimulating oxidative stress through different signaling pathways that include tyrosine kinases and mitogen-activated protein kinases to induce inflammation and fibrosis in blood vessels, the kidney, and the heart. The actions of aldosterone also lead to endothelial dysfunction, which participates in its effects on target organs, including progression of hypertension. Blockade of mineralocorticoid receptor or inhibition of aldosterone generation lowers BP and protects target organs, reducing progression of CKD. All these actions are reviewed, with an emphasis on the effects on the kidney.\n                  <\/jats:p>","DOI":"10.34067\/kid.0000000929","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T16:01:32Z","timestamp":1753200092000},"page":"2017-2027","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Interplay Between the Mineralocorticoid System, Inflammation, Hypertension, and Kidney Disease"],"prefix":"10.34067","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2469-4644","authenticated-orcid":false,"given":"Eviatar","family":"Fields","sequence":"first","affiliation":[{"name":"Department of Medicine, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4502-2823","authenticated-orcid":false,"given":"Ernesto L.","family":"Schiffrin","sequence":"additional","affiliation":[{"name":"Department of Medicine, McGill University, Montreal, Quebec, Canada"},{"name":"Hypertension and Vascular Research Unit, Lady Davis Institute for Medical Research, Montreal, Quebec, Canada"},{"name":"Department of Medicine, Sir Mortimer B. Davis-Jewish General Hospital, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"issue":"2","key":"B1-20251120","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s11906-011-0182-2","article-title":"The role of aldosterone in the metabolic syndrome","volume":"13","author":"Briet","year":"2011","journal-title":"Curr Hypertens Rep."},{"issue":"5","key":"B2-20251120","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1053\/j.ajkd.2022.04.016","article-title":"Aldosterone, mineralocorticoid receptor activation, and CKD: a review of evolving treatment paradigms","volume":"80","author":"Epstein","year":"2022","journal-title":"Am J Kidney Dis."},{"issue":"1","key":"B3-20251120","doi-asserted-by":"crossref","first-page":"F7","DOI":"10.1530\/JOE-16-0160","article-title":"Focused review: obesity, hypertension and aldosterone: is leptin the link?","volume":"230","author":"Xie","year":"2016","journal-title":"J Endocrinol."},{"issue":"11","key":"B4-20251120","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/ajh\/hpy120","article-title":"Mineralocorticoid receptor and cardiovascular disease","volume":"31","author":"Buonafine","year":"2018","journal-title":"Am J Hypertens."},{"issue":"1","key":"B5-20251120","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3390\/biomedicines13010053","article-title":"Recent advances and perspectives on the use of mineralocorticoid receptor antagonists for the treatment of hypertension and chronic kidney disease: a review","volume":"13","author":"Miyasako","year":"2024","journal-title":"Biomedicines."},{"issue":"2","key":"B6-20251120","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/HYPERTENSIONAHA.114.04488","article-title":"Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases","volume":"65","author":"Bauersachs","year":"2015","journal-title":"Hypertension."},{"issue":"5","key":"B7-20251120","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrneph.2010.30","article-title":"Aldosterone: effects on the kidney and cardiovascular system","volume":"6","author":"Briet","year":"2010","journal-title":"Nat Rev Nephrol."},{"issue":"6","key":"B8-20251120","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1161\/CIRCULATIONAHA.115.018912","article-title":"Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries","volume":"134","author":"Mills","year":"2016","journal-title":"Circulation."},{"issue":"12","key":"B9-20251120","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1093\/ajh\/hpx064","article-title":"The potential role of primary care in case detection\/screening of primary aldosteronism","volume":"30","author":"Kline","year":"2017","journal-title":"Am J Hypertens."},{"issue":"14","key":"B10-20251120","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/j.jacc.2017.01.052","article-title":"Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice","volume":"69","author":"Monticone","year":"2017","journal-title":"J Am Coll Cardiol."},{"issue":"1","key":"B11-20251120","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa033263","article-title":"Serum aldosterone and the incidence of hypertension in nonhypertensive persons","volume":"351","author":"Vasan","year":"2004","journal-title":"New Engl J Med."},{"issue":"12","key":"B12-20251120","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1210\/clinem\/dgaa606","article-title":"Evolution of the primary aldosteronism syndrome: updating the approach","volume":"105","author":"Vaidya","year":"2020","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"B13-20251120","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1161\/HYPERTENSIONAHA.124.24153","article-title":"Characterizing the origins of primary aldosteronism","volume":"82","author":"Brown","year":"2025","journal-title":"Hypertension."},{"issue":"6","key":"B14-20251120","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1161\/HYPERTENSIONAHA.125.24648","article-title":"Nationwide, pragmatic, direct-to-patient primary aldosteronism testing program","volume":"82","author":"Brown","year":"2025","journal-title":"Hypertension."},{"issue":"9","key":"B15-20251120","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/ajh\/hpae051","article-title":"New kids on the hypertension block: novel agents with new mechanisms of action","volume":"37","author":"Schiffrin","year":"2024","journal-title":"Am J Hypertens."},{"issue":"2","key":"B16-20251120","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s12020-021-02704-2","article-title":"Higher risk of chronic kidney disease and progressive kidney function impairment in primary aldosteronism than in essential hypertension. Case-control study","volume":"73","author":"Fern\u00e1ndez-Arg\u00fceso","year":"2021","journal-title":"Endocrine."},{"issue":"1","key":"B17-20251120","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/HJH.0000000000002216","article-title":"Renal damage in primary aldosteronism: a systematic review and meta-analysis","volume":"38","author":"Monticone","year":"2020","journal-title":"J Hypertens."},{"issue":"1","key":"B18-20251120","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/ajh\/hpaa137","article-title":"Aldosterone, inflammation, immune system, and hypertension","volume":"34","author":"Ferreira","year":"2021","journal-title":"Am J Hypertens."},{"issue":"10","key":"B19-20251120","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"New Engl J Med."},{"issue":"24","key":"B20-20251120","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"New Engl J Med."},{"issue":"14","key":"B21-20251120","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"New Engl J Med."},{"issue":"15","key":"B22-20251120","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"New Engl J Med."},{"issue":"1","key":"B23-20251120","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"New Engl J Med."},{"issue":"1","key":"B24-20251120","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12882-016-0337-0","article-title":"Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis","volume":"17","author":"Currie","year":"2016","journal-title":"BMC Nephrol."},{"issue":"4","key":"B25-20251120","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.amjcard.2019.11.014","article-title":"Efficacy and safety of mineralocorticoid receptor antagonists in patients with heart failure and chronic kidney disease","volume":"125","author":"Khan","year":"2020","journal-title":"Am J Cardiol."},{"issue":"6","key":"B26-20251120","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ahj.2017.03.011","article-title":"True rate of mineralocorticoid receptor antagonists-related hyperkalemia in placebo-controlled trials: a meta-analysis","volume":"188","author":"Vukadinovi\u0107","year":"2017","journal-title":"Am Heart J."},{"issue":"23","key":"B27-20251120","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"New Engl J Med."},{"issue":"6","key":"B28-20251120","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J."},{"issue":"10","key":"B29-20251120","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/ki.2011.48","article-title":"Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease","volume":"79","author":"Bertocchio","year":"2011","journal-title":"Kidney Int."},{"issue":"2","key":"B30-20251120","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41371-020-0360-2","article-title":"Structural determinants of activation of the mineralocorticoid receptor: an evolutionary perspective","volume":"35","author":"Fuller","year":"2021","journal-title":"J Hum Hypertens."},{"issue":"16","key":"B31-20251120","doi-asserted-by":"crossref","first-page":"9424","DOI":"10.1073\/pnas.95.16.9424","article-title":"Mineralocorticoid receptor knockout mice: pathophysiology of Na+ metabolism","volume":"95","author":"Berger","year":"1998","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"6","key":"B32-20251120","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1161\/01.HYP.0000193502.77417.17","article-title":"Mechanisms of mineralocorticoid action","volume":"46","author":"Fuller","year":"2005","journal-title":"Hypertension."},{"issue":"9","key":"B33-20251120","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/s41581-019-0167-y","article-title":"The role of sodium in modulating immune cell function","volume":"15","author":"Wilck","year":"2019","journal-title":"Nat Rev Nephrol."},{"issue":"5","key":"B34-20251120","first-page":"543","article-title":"The immune system: role in hypertension","volume":"29","author":"Schiffrin","year":"2013","journal-title":"Can J Cardiol."},{"issue":"6","key":"B35-20251120","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.kint.2017.12.016","article-title":"The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling","volume":"93","author":"Barrera-Chimal","year":"2018","journal-title":"Kidney Int."},{"issue":"10","key":"B36-20251120","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1161\/CIRCRESAHA.116.310480","article-title":"T-Cell mineralocorticoid receptor controls blood pressure by regulating interferon-gamma","volume":"120","author":"Sun","year":"2017","journal-title":"Circ Res."},{"issue":"14","key":"B37-20251120","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1093\/eurheartj\/ehae670","article-title":"Dendritic cell mineralocorticoid receptor controls blood pressure by regulating T helper 17 differentiation: role of the Plc\u03b21\/4\u2013Stat5\u2013NF-\u03baB pathway","volume":"46","author":"Wang","year":"2025","journal-title":"Eur Heart J."},{"issue":"5","key":"B38-20251120","doi-asserted-by":"crossref","first-page":"F1178","DOI":"10.1152\/ajprenal.00532.2009","article-title":"Direct fibrogenic effects of aldosterone on normotensive kidney: an effect modified by 11\u03b2-HSD activity","volume":"298","author":"Brem","year":"2010","journal-title":"Am J Physiol Renal Physiol."},{"issue":"1","key":"B39-20251120","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1046\/j.1523-1755.2003.00707.x","article-title":"Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity","volume":"63","author":"Feria","year":"2003","journal-title":"Kidney Int."},{"issue":"23","key":"B40-20251120","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1161\/CIRCULATIONAHA.104.521625","article-title":"Aldosterone synthase inhibitor ameliorates angiotensin II\u2013induced organ damage","volume":"111","author":"Fiebeler","year":"2005","journal-title":"Circulation."},{"issue":"5","key":"B41-20251120","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1161\/01.HYP.22.5.754","article-title":"Early interstitial changes in hypertension-induced renal injury","volume":"22","author":"Mai","year":"1993","journal-title":"Hypertension."},{"issue":"1 Pt 2","key":"B42-20251120","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1161\/01.HYP.33.1.389","article-title":"Monocyte infiltration and adhesion molecules in a rat model of high human renin hypertension","volume":"33","author":"Mervaala","year":"1999","journal-title":"Hypertension."},{"issue":"6","key":"B43-20251120","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1159\/000074454","article-title":"Prevention of hypertension attenuates albuminuria and renal expression of fibronectin in diabetic spontaneously hypertensive rats","volume":"23","author":"Pavan","year":"2003","journal-title":"Am J Nephrol."},{"issue":"1","key":"B44-20251120","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1161\/01.HYP.0000078357.92682.EC","article-title":"Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling","volume":"42","author":"Pu","year":"2003","journal-title":"Hypertension."},{"issue":"5","key":"B45-20251120","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1046\/j.1523-1755.2003.00929.x","article-title":"Aldosterone\/salt induces renal inflammation and fibrosis in hypertensive rats","volume":"63","author":"Blasi","year":"2003","journal-title":"Kidney Int."},{"issue":"1","key":"B46-20251120","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1053\/ajkd.2001.25209","article-title":"Glomerular osteopontin expression and macrophage infiltration in glomerulosclerosis of DOCA\u2013salt rats","volume":"38","author":"Hartner","year":"2001","journal-title":"Am J Kidney Dis."},{"issue":"9","key":"B47-20251120","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/ki.2009.9","article-title":"Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt","volume":"75","author":"Lea","year":"2009","journal-title":"Kidney Int."},{"issue":"3","key":"B48-20251120","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1096\/fj.10-173286","article-title":"Mineralocorticoid receptor-mediated DNA damage in kidneys of DOCA-salt hypertensive rats","volume":"25","author":"Schupp","year":"2011","journal-title":"FASEB J."},{"issue":"5","key":"B49-20251120","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1161\/01.HYP.19.5.464","article-title":"Renal injury from angiotensin II-mediated hypertension","volume":"19","author":"Johnson","year":"1992","journal-title":"Hypertension."},{"issue":"6","key":"B50-20251120","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1038\/s41440-019-0211-0","article-title":"Effect of a novel nonsteroidal selective mineralocorticoid receptor antagonist, esaxerenone (CS-3150), on blood pressure and renal injury in high salt-treated type 2 diabetic mice","volume":"42","author":"Bhuiyan","year":"2019","journal-title":"Hypertens Res."},{"key":"B51-20251120","doi-asserted-by":"crossref","first-page":"114208","DOI":"10.1016\/j.intimp.2025.114208","article-title":"Proliferation of renal macrophage via MR\/CSF1 pathway induced with aldosterone and inhibited by esaxerenone","volume":"149","author":"Liu","year":"2025","journal-title":"Int Immunopharmacol."},{"key":"B52-20251120","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.matbio.2017.11.010","article-title":"Inflammation and fibrosis","volume":"68-69","author":"Mack","year":"2018","journal-title":"Matrix Biol."},{"issue":"3","key":"B53-20251120","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/ki.1997.106","article-title":"Effects of early and late antihypertensive treatment on extracellular matrix proteins and mononuclear cells in uninephrectomized SHR","volume":"51","author":"Geiger","year":"1997","journal-title":"Kidney Int."},{"issue":"suppl 48","key":"B54-20251120","doi-asserted-by":"crossref","first-page":"25S","DOI":"10.1042\/CS103S025S","article-title":"Contribution of endothelin-1 to renal activator protein-1 activation and macrophage infiltration in aldosterone-induced hypertension","volume":"103","author":"Tostes","year":"2002","journal-title":"Clin Sci (Lond)."},{"issue":"1","key":"B55-20251120","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1053\/j.ajkd.2008.03.023","article-title":"Associations of glomerular number and birth weight with clinicopathological features of African Americans and whites","volume":"52","author":"Hughson","year":"2008","journal-title":"Am J Kidney Dis."},{"issue":"6","key":"B56-20251120","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306010","article-title":"Renal denervation prevents immune cell activation and renal inflammation in angiotensin II\u2013induced hypertension","volume":"117","author":"Xiao","year":"2015","journal-title":"Circ Res."},{"issue":"1","key":"B57-20251120","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1161\/HYPERTENSIONAHA.113.00689","article-title":"Immunosenescent CD8+ T cells and C-X-C chemokine receptor type 3 chemokines are increased in human hypertension","volume":"62","author":"Youn","year":"2013","journal-title":"Hypertension."},{"issue":"10","key":"B58-20251120","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1161\/01.ATV.0000181743.28028.57","article-title":"Reduced vascular remodeling, endothelial dysfunction, and oxidative stress in resistance arteries of angiotensin II-infused macrophage colony-stimulating factor-deficient mice: evidence for a role in inflammation in angiotensin-induced vascular injury","volume":"25","author":"De Ciuceis","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"4","key":"B59-20251120","doi-asserted-by":"crossref","first-page":"H1789","DOI":"10.1152\/ajpheart.01118.2006","article-title":"Resistance artery remodeling in deoxycorticosterone acetate-salt hypertension is dependent on vascular inflammation: evidence from m-CSF-deficient mice","volume":"292","author":"Ko","year":"2007","journal-title":"Am J Physiol Heart Circ Physiol."},{"issue":"10","key":"B60-20251120","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1084\/jem.20070657","article-title":"Role of the T cell in the genesis of angiotensin II\u2013induced hypertension and vascular dysfunction","volume":"204","author":"Guzik","year":"2007","journal-title":"J Exp Med."},{"issue":"3","key":"B61-20251120","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1161\/HYPERTENSIONAHA.113.02191","article-title":"CD247 modulates blood pressure by altering T-lymphocyte infiltration in the kidney","volume":"63","author":"Rudemiller","year":"2014","journal-title":"Hypertension."},{"issue":"22","key":"B62-20251120","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1161\/CIRCULATIONAHA.116.027058","article-title":"\u03b3\u03b4 T cells mediate angiotensin II-induced hypertension and vascular injury","volume":"135","author":"Caillon","year":"2017","journal-title":"Circulation."},{"key":"B63-20251120","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3389\/fphys.2018.00473","article-title":"Macrophage depletion lowered blood pressure and attenuated hypertensive renal injury and fibrosis","volume":"9","author":"Huang","year":"2018","journal-title":"Front Physiol."},{"issue":"2","key":"B64-20251120","doi-asserted-by":"crossref","first-page":"F191","DOI":"10.1152\/ajprenal.0197.2001","article-title":"Reduction of renal immune cell infiltration results in blood pressure control in genetically hypertensive rats","volume":"282","author":"Rodr\u00edguez-Iturbe","year":"2002","journal-title":"Am J Physiol Renal Physiol."},{"issue":"3","key":"B65-20251120","doi-asserted-by":"crossref","first-page":"H938","DOI":"10.1152\/ajpheart.00707.2009","article-title":"Immune regulation and vascular inflammation in genetic hypertension","volume":"298","author":"Viel","year":"2010","journal-title":"Am J Physiol Heart Circ Physiol."},{"issue":"3","key":"B66-20251120","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1161\/HYPERTENSIONAHA.110.162941","article-title":"T regulatory lymphocytes prevent angiotensin II-induced hypertension and vascular injury","volume":"57","author":"Barhoumi","year":"2011","journal-title":"Hypertension."},{"issue":"2","key":"B67-20251120","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1161\/HYPERTENSIONAHA.111.181123","article-title":"T regulatory lymphocytes prevent aldosterone-induced vascular injury","volume":"59","author":"Kasal","year":"2012","journal-title":"Hypertension."},{"issue":"9","key":"B68-20251120","doi-asserted-by":"crossref","first-page":"3899","DOI":"10.1096\/fj.15-271734","article-title":"Excess aldosterone is a critical danger signal for inflammasome activation in the development of renal fibrosis in mice","volume":"29","author":"Kadoya","year":"2015","journal-title":"FASEB J."},{"issue":"7","key":"B69-20251120","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1159\/000524940","article-title":"Finerenone reduces renal ROR\u03b3t \u03b3\u03b4 T cells and protects against cardiorenal damage","volume":"53","author":"Luettges","year":"2022","journal-title":"Am J Nephrol."},{"issue":"4","key":"B70-20251120","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1161\/HYPERTENSIONAHA.113.02883","article-title":"Spironolactone decreases DOCA\u2013salt\u2013induced organ damage by blocking the activation of T helper 17 and the downregulation of regulatory T lymphocytes","volume":"63","author":"Amador","year":"2014","journal-title":"Hypertension."},{"issue":"3","key":"B71-20251120","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1161\/HYPERTENSIONAHA.109.131110","article-title":"Deletion of mineralocorticoid receptors from macrophages protects against Deoxycorticosterone\/salt-induced cardiac fibrosis and increased blood pressure","volume":"54","author":"Rickard","year":"2009","journal-title":"Hypertension."},{"key":"B72-20251120","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.trsl.2017.10.011","article-title":"Macrophages under pressure: the role of macrophage polarization in hypertension","volume":"191","author":"Harwani","year":"2018","journal-title":"Transl Res."},{"issue":"24","key":"B73-20251120","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1161\/CIRCULATIONAHA.109.930446","article-title":"Inhibition and genetic ablation of the B7\/CD28 T-cell costimulation axis prevents experimental hypertension","volume":"122","author":"Vinh","year":"2010","journal-title":"Circulation."},{"issue":"6","key":"B74-20251120","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCRESAHA.116.303697","article-title":"Inflammation, immunity, and hypertensive end-organ damage","volume":"116","author":"McMaster","year":"2015","journal-title":"Circ Res."},{"issue":"12","key":"B75-20251120","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.34067\/KID.0001292022","article-title":"IFN-\u03b3 contributes to the immune mechanisms of hypertension","volume":"3","author":"Benson","year":"2022","journal-title":"Kidney360."},{"issue":"3","key":"B76-20251120","doi-asserted-by":"crossref","first-page":"H923","DOI":"10.1152\/ajpheart.01278.2005","article-title":"An emerging role for inflammatory cytokines in hypertension","volume":"290","author":"Granger","year":"2006","journal-title":"Am J Physiol Heart Circ Physiol."},{"issue":"82","key":"B77-20251120","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1046\/j.1523-1755.62.s82.4.x","article-title":"Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney","volume":"62","author":"Ruiz-Ortega","year":"2002","journal-title":"Kidney Int."},{"issue":"12","key":"B78-20251120","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1093\/ndt\/17.12.2145","article-title":"Transforming growth factor-beta(1) in the kidney and urine of patients with glomerular disease and proteinuria","volume":"17","author":"Goumenos","year":"2002","journal-title":"Nephrol Dial Transplant."},{"issue":"1","key":"B79-20251120","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12882-015-0068-7","article-title":"Association of C-reactive protein, tumor necrosis factor-alpha, and interleukin-6 with chronic kidney disease","volume":"16","author":"Lee","year":"2015","journal-title":"BMC Nephrol."},{"issue":"10","key":"B80-20251120","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1161\/CIRCULATIONAHA.105.539122","article-title":"Increased expression of mineralocorticoid effector mechanisms in kidney biopsies of patients with heavy proteinuria","volume":"112","author":"Quinkler","year":"2005","journal-title":"Circulation."},{"issue":"2","key":"B81-20251120","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/ki.1994.291","article-title":"Expression of transforming growth factor-beta 1 during diabetic renal hypertrophy","volume":"46","author":"Shankland","year":"1994","journal-title":"Kidney Int."},{"issue":"9","key":"B82-20251120","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3109\/08860220903150312","article-title":"Antifibrotic effects of aldosterone receptor blocker (spironolactone) in patients with chronic kidney disease","volume":"31","author":"Guney","year":"2009","journal-title":"Ren Fail."},{"issue":"5","key":"B83-20251120","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1161\/HYPERTENSIONAHA.110.158071","article-title":"Interleukin 6 knockout prevents angiotensin II hypertension: role of renal vasoconstriction and janus kinase 2\/signal transducer and activator of transcription 3 activation","volume":"56","author":"Brands","year":"2010","journal-title":"Hypertension."},{"issue":"3","key":"B84-20251120","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1161\/HYPERTENSIONAHA.114.04975","article-title":"Renal transporter activation during angiotensin-II hypertension is blunted in interferon-\u03b3-\/- and interleukin-17A-\/- mice","volume":"65","author":"Kamat","year":"2015","journal-title":"Hypertension."},{"issue":"3","key":"B85-20251120","doi-asserted-by":"crossref","first-page":"H935","DOI":"10.1152\/ajpheart.00708.2005","article-title":"Angiotensin II hypertension is attenuated in interleukin-6 knockout mice","volume":"290","author":"Lee","year":"2006","journal-title":"Am J Physiol Heart Circ Physiol."},{"issue":"3","key":"B86-20251120","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1172\/JCI76327","article-title":"Lymphocyte adaptor protein LNK deficiency exacerbates hypertension and end-organ inflammation","volume":"125","author":"Saleh","year":"2015","journal-title":"J Clin Invest."},{"issue":"11","key":"B87-20251120","doi-asserted-by":"crossref","first-page":"F1455","DOI":"10.1152\/ajprenal.00645.2011","article-title":"Genetic deficiency of Smad3 protects the kidneys from atrophy and interstitial fibrosis in 2K1C hypertension","volume":"302","author":"Warner","year":"2012","journal-title":"Am J Physiol Renal Physiol."},{"issue":"6","key":"B88-20251120","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1161\/HYPERTENSIONAHA.114.03863","article-title":"Tumor necrosis Factor-\u03b1 produced in the kidney contributes to angiotensin II\u2013dependent hypertension","volume":"64","author":"Zhang","year":"2014","journal-title":"Hypertension."},{"key":"B89-20251120","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.3389\/fphar.2019.01015","article-title":"Interleukin 17A participates in renal inflammation associated to experimental and human hypertension","volume":"10","author":"Orejudo","year":"2019","journal-title":"Front Pharmacol."},{"issue":"5","key":"B90-20251120","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1161\/HYPERTENSIONAHA.116.08526","article-title":"Nonsteroidal mineralocorticoid receptor antagonist finerenone protects against acute kidney injury-mediated chronic kidney disease: role of oxidative stress","volume":"69","author":"Lattenist","year":"2017","journal-title":"Hypertension."},{"issue":"5","key":"B91-20251120","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1161\/01.HYP.0000160404.08866.5a","article-title":"Antioxidant treatment prevents renal damage and dysfunction and reduces arterial pressure in salt-sensitive hypertension","volume":"45","author":"Tian","year":"2005","journal-title":"Hypertension."},{"issue":"6","key":"B92-20251120","doi-asserted-by":"crossref","first-page":"H3388","DOI":"10.1152\/ajpheart.00981.2007","article-title":"Interactions between oxidative stress and inflammation in salt-sensitive hypertension","volume":"293","author":"Tian","year":"2007","journal-title":"Am J Physiol Heart Circ Physiol."},{"issue":"6","key":"B93-20251120","doi-asserted-by":"crossref","first-page":"R1858","DOI":"10.1152\/ajpregu.90650.2008","article-title":"NADPH oxidase contributes to renal damage and dysfunction in dahl salt-sensitive hypertension","volume":"295","author":"Tian","year":"2008","journal-title":"Am J Physiol Regul Integr Comp Physiol."},{"issue":"3","key":"B94-20251120","first-page":"343","article-title":"Increased reactive oxygen species contributes to kidney injury in mineralocorticoid hypertensive rats","volume":"57","author":"Jin","year":"2006","journal-title":"J Physiol Pharmacol."},{"issue":"7","key":"B95-20251120","doi-asserted-by":"crossref","first-page":"e41896","DOI":"10.1371\/journal.pone.0041896","article-title":"Oxidative stress-induced glomerular mineralocorticoid receptor activation limits the benefit of salt reduction in dahl salt-sensitive rats","volume":"7","author":"Kitada","year":"2012","journal-title":"PLoS One."},{"issue":"7","key":"B96-20251120","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0895-7061(04)00811-8","article-title":"Involvement of oxidative stress in the profibrotic action of aldosterone interaction with the renin-angiotensin system","volume":"17","author":"Iglarz","year":"2004","journal-title":"Am J Hypertens."},{"issue":"5","key":"B97-20251120","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/sj.cdd.4401843","article-title":"Signals from within: the DNA-damage-induced NF-kappaB response","volume":"13","author":"Janssens","year":"2006","journal-title":"Cell Death Differ."},{"key":"B98-20251120","doi-asserted-by":"crossref","DOI":"10.1681\/ASN.0000000711","article-title":"The purinoreceptor P2X7 in extracellular ATP-mediated inflammation through the spectrum of kidney diseases and kidney","author":"T\u00e9llez Garcia","year":"2025","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"B99-20251120","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41581-020-0304-7","article-title":"Conversion of extracellular ATP into adenosine: a master switch in renal health and disease","volume":"16","author":"Dwyer","year":"2020","journal-title":"Nat Rev Nephrol."},{"issue":"10","key":"B100-20251120","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1681\/ASN.2010020143","article-title":"The NLRP3 inflammasome promotes renal inflammation and contributes to CKD","volume":"21","author":"Vilaysane","year":"2010","journal-title":"J Am Soc Nephrol."},{"issue":"3","key":"B101-20251120","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S0022-2143(97)90178-5","article-title":"Increased serum levels of interleukin-1\u03b2 in the systemic circulation of patients with essential hypertension: additional risk factor for atherogenesis in hypertensive patients?","volume":"129","author":"Dalekos","year":"1997","journal-title":"J Lab Clin Med."},{"issue":"1","key":"B102-20251120","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3109\/08037051.2014.940710","article-title":"Increased arterial stiffness in resistant hypertension is associated with inflammatory biomarkers","volume":"24","author":"Barbaro","year":"2015","journal-title":"Blood Press."},{"issue":"1","key":"B103-20251120","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12964-020-00558-1","article-title":"Blocking connexin-43 mediated hemichannel activity protects against early tubular injury in experimental chronic kidney disease","volume":"18","author":"Price","year":"2020","journal-title":"Cell Commun Signal."},{"key":"B104-20251120","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ebiom.2017.04.011","article-title":"Hyperglycemia-induced renal P2X7 receptor activation enhances diabetes-related injury","volume":"19","author":"Menzies","year":"2017","journal-title":"EBioMedicine."},{"issue":"3","key":"B105-20251120","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/path.4237","article-title":"The purinergic 2X7 receptor participates in renal inflammation and injury induced by high-fat diet: possible role of NLRP3 inflammasome activation","volume":"231","author":"Solini","year":"2013","journal-title":"J Pathol."},{"issue":"36","key":"B106-20251120","doi-asserted-by":"crossref","first-page":"eaau6426","DOI":"10.1126\/sciimmunol.aau6426","article-title":"ATP release drives heightened immune responses associated with hypertension","volume":"4","author":"Zhao","year":"2019","journal-title":"Sci Immunol."},{"issue":"18","key":"B107-20251120","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.1113\/jphysiol.2014.271676","article-title":"Pressure natriuresis and the renal control of arterial blood pressure","volume":"592","author":"Ivy","year":"2014","journal-title":"J Physiol."},{"issue":"2","key":"B108-20251120","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/hr.2011.153","article-title":"P2X7 receptor antagonism attenuates the hypertension and renal injury in dahl salt-sensitive rats","volume":"35","author":"Ji","year":"2012","journal-title":"Hypertens Res."},{"issue":"1","key":"B109-20251120","doi-asserted-by":"crossref","first-page":"F9","DOI":"10.1152\/ajprenal.00663.2016","article-title":"Physiopathological implications of P2X1 and P2X7 receptors in regulation of glomerular hemodynamics in angiotensin II-induced hypertension","volume":"313","author":"Franco","year":"2017","journal-title":"Am J Physiol Renal Physiol."},{"issue":"5","key":"B110-20251120","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/ki.2015.182","article-title":"Inhibition of the purinergic P2X7 receptor improves renal perfusion in angiotensin-II-infused rats","volume":"88","author":"Menzies","year":"2015","journal-title":"Kidney Int."},{"issue":"11","key":"B111-20251120","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1097\/HJH.0000000000003520","article-title":"P2RX7 gene knockout or antagonism reduces angiotensin II-induced hypertension, vascular injury and immune cell activation","volume":"41","author":"Shokoples","year":"2023","journal-title":"J Hypertens."},{"issue":"8","key":"B112-20251120","doi-asserted-by":"crossref","first-page":"F1207","DOI":"10.1152\/ajprenal.00051.2012","article-title":"P2X7 deficiency attenuates hypertension and renal injury in deoxycorticosterone acetate-salt hypertension","volume":"303","author":"Ji","year":"2012","journal-title":"Am J Physiol Renal Physiol."},{"issue":"6","key":"B113-20251120","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1096\/fj.08-126458","article-title":"Autocrine regulation of T-cell activation by ATP release and P2X7 receptors","volume":"23","author":"Yip","year":"2009","journal-title":"FASEB J."},{"issue":"12","key":"B114-20251120","doi-asserted-by":"crossref","first-page":"6436","DOI":"10.4049\/jimmunol.168.12.6436","article-title":"Absence of the P2X7 receptor alters leukocyte function and attenuates an inflammatory response","volume":"168","author":"Labasi","year":"2002","journal-title":"J Immunol."},{"issue":"3","key":"B115-20251120","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1161\/HYPERTENSIONAHA.123.21819","article-title":"P2X7-Mediated antigen-independent activation of CD8+ T cells promotes salt sensitive hypertension","volume":"81","author":"Benson","year":"2024","journal-title":"Hypertension."},{"issue":"10","key":"B116-20251120","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1096\/fj.14-267393","article-title":"IL-1\u03b2 production is dependent on the activation of purinergic receptors and NLRP3 pathway in human macrophages","volume":"29","author":"Gicquel","year":"2015","journal-title":"FASEB J."},{"issue":"1","key":"B117-20251120","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s12882-020-01861-2","article-title":"Brilliant blue G, a P2X7 receptor antagonist, attenuates early phase of renal inflammation, interstitial fibrosis and is associated with renal cell proliferation in ureteral obstruction in rats","volume":"21","author":"Pereira","year":"2020","journal-title":"BMC Nephrol."},{"key":"B118-20251120","doi-asserted-by":"crossref","first-page":"117640","DOI":"10.1016\/j.lfs.2020.117640","article-title":"Inhibition of the P2X7 receptor improves renal function via renin-angiotensin system and nitric oxide on diabetic nephropathy in rats","volume":"251","author":"Nascimento","year":"2020","journal-title":"Life Sci."},{"issue":"9","key":"B119-20251120","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/sj.ki.5001804","article-title":"The role of purinergic P2X7 receptors in the inflammation and fibrosis of unilateral ureteral obstruction in mice","volume":"70","author":"Gon\u00e7alves","year":"2006","journal-title":"Kidney Int."},{"issue":"12","key":"B120-20251120","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.3390\/cells8121595","article-title":"NLRP3 inflammasome and mineralocorticoid receptors are associated with vascular dysfunction in type 2 diabetes mellitus","volume":"8","author":"Ferreira","year":"2019","journal-title":"Cells."},{"issue":"23","key":"B121-20251120","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1161\/CIRCULATIONAHA.116.024369","article-title":"NLRP3 inflammasome mediates aldosterone-induced vascular damage","volume":"134","author":"Bruder-Nascimento","year":"2016","journal-title":"Circulation."},{"issue":"4","key":"B122-20251120","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1093\/cvr\/cvy252","article-title":"Pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure, renal damage, and dysfunction in salt-sensitive hypertension","volume":"115","author":"Krishnan","year":"2019","journal-title":"Cardiovasc Res."},{"issue":"4","key":"B123-20251120","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/bph.13230","article-title":"Inflammasome activity is essential for one kidney\/deoxycorticosterone acetate\/salt-induced hypertension in mice","volume":"173","author":"Krishnan","year":"2016","journal-title":"Br J Pharmacol."},{"issue":"9","key":"B124-20251120","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1097\/HJH.0000000000002880","article-title":"Aldosterone contributes to hypertension in male mice inducibly overexpressing human endothelin-1 in endothelium","volume":"39","author":"Berillo","year":"2021","journal-title":"J Hypertens."},{"issue":"675","key":"B125-20251120","doi-asserted-by":"crossref","first-page":"eabf5074","DOI":"10.1126\/scitranslmed.abf5074","article-title":"Endothelin blockade prevents the long-term cardiovascular and renal sequelae of acute kidney injury in mice","volume":"14","author":"Czopek","year":"2022","journal-title":"Sci Transl Med."},{"issue":"5","key":"B126-20251120","doi-asserted-by":"crossref","first-page":"F1433","DOI":"10.1152\/ajprenal.00101.2007","article-title":"Fractional urinary excretion of endothelin-1 is reduced by acute ETB receptor blockade","volume":"293","author":"Goddard","year":"2007","journal-title":"Am J Physiol Renal Physiol."},{"issue":"2","key":"B127-20251120","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/ki.1993.53","article-title":"Renal endothelin gene expression is increased in remnant kidney and correlates with disease progression","volume":"43","author":"Orisio","year":"1993","journal-title":"Kidney Int."},{"issue":"2","key":"B128-20251120","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1161\/HYPERTENSIONAHA.115.05168","article-title":"Inducible human endothelin-1 overexpression in endothelium raises blood pressure via endothelin type A receptors","volume":"66","author":"Rautureau","year":"2015","journal-title":"Hypertension."},{"issue":"6","key":"B129-20251120","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1172\/JCI119297","article-title":"Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension","volume":"99","author":"Hocher","year":"1997","journal-title":"J Clin Invest."},{"issue":"2","key":"B130-20251120","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00109-001-0284-4","article-title":"Renal damage and salt-dependent hypertension in aged transgenic mice overexpressing endothelin-1","volume":"80","author":"Shindo","year":"2002","journal-title":"J Mol Med."},{"issue":"2 Pt 2","key":"B131-20251120","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1161\/01.HYP.37.2.490","article-title":"Regression of renal vascular fibrosis by endothelin receptor antagonism","volume":"37","author":"Boffa","year":"2001","journal-title":"Hypertension."},{"issue":"6","key":"B132-20251120","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1161\/01.HYP.37.6.1444","article-title":"ETA receptor antagonist prevents blood pressure elevation and vascular remodeling in aldosterone-infused rats","volume":"37","author":"Park","year":"2001","journal-title":"Hypertension."},{"issue":"2 Pt 1","key":"B133-20251120","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0895-7061(01)02291-9","article-title":"Cardiac and vascular fibrosis and hypertrophy in aldosterone-infused rats: role of endothelin-1","volume":"15","author":"Park","year":"2002","journal-title":"Am J Hypertens."},{"issue":"1","key":"B134-20251120","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1161\/HYPERTENSIONAHA.117.09925","article-title":"Three-month endothelial human endothelin-1 overexpression causes blood pressure elevation and vascular and kidney injury","volume":"71","author":"Coelho","year":"2018","journal-title":"Hypertension."},{"key":"B135-20251120","doi-asserted-by":"crossref","first-page":"118223","DOI":"10.1016\/j.lfs.2020.118223","article-title":"Endothelin converting enzyme-1 (ECE-1) deletion in association with endothelin-1 downregulation ameliorates kidney fibrosis in mice","volume":"258","author":"Arfian","year":"2020","journal-title":"Life Sci."},{"issue":"2","key":"B136-20251120","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/ki.1995.61","article-title":"Effect of a specific endothelin A receptor antagonist on murine lupus nephritis","volume":"47","author":"Nakamura","year":"1995","journal-title":"Kidney Int."},{"issue":"2","key":"B137-20251120","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1161\/CIRCRESAHA.124.324890","article-title":"ET-3\/ETBR mediates Na+-activated immune signaling and kidney lymphatic dynamics","volume":"136","author":"Mutchler","year":"2025","journal-title":"Circ Res."},{"issue":"1","key":"B138-20251120","doi-asserted-by":"crossref","first-page":"9976","DOI":"10.1038\/s41598-024-60636-z","article-title":"Eplerenone reduces lymphangiogenesis in the contralateral kidneys of UUO rats","volume":"14","author":"Hao","year":"2024","journal-title":"Sci Rep."},{"issue":"6","key":"B139-20251120","first-page":"606","article-title":"The selective mineralocorticoid receptor antagonist eplerenone is protective in mild anti-GBM glomeru-lonephritis","volume":"4","author":"Zitt","year":"2011","journal-title":"Int J Clin Exp Pathol."},{"issue":"10184","key":"B140-20251120","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/S0140-6736(19)30772-X","article-title":"Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial","volume":"393","author":"Heerspink","year":"2019","journal-title":"Lancet."},{"issue":"1","key":"B141-20251120","doi-asserted-by":"crossref","first-page":"e14411","DOI":"10.1111\/dme.14411","article-title":"Efficacy and safety of endothelin receptor antagonists in type 2 diabetic kidney disease: a systematic review and meta-analysis of randomized controlled trials","volume":"38","author":"Zhou","year":"2021","journal-title":"Diabet Med."},{"issue":"10367","key":"B142-20251120","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/S0140-6736(22)02034-7","article-title":"Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial","volume":"400","author":"Schlaich","year":"2022","journal-title":"Lancet."},{"issue":"1","key":"B143-20251120","doi-asserted-by":"crossref","first-page":"25909","DOI":"10.31083\/RCM25909","article-title":"Efficacy and safety of aprocitentan in the treatment of hypertension: a meta-analysis of evidence from randomized controlled trials","volume":"26","author":"Zheng","year":"2025","journal-title":"Rev Cardiovasc Med."},{"issue":"1","key":"B144-20251120","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1038\/s41598-018-23278-6","article-title":"Rac1 in podocytes promotes glomerular repair and limits the formation of sclerosis","volume":"8","author":"Asao","year":"2018","journal-title":"Sci Rep."},{"issue":"1","key":"B145-20251120","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1152\/physrev.2001.81.1.153","article-title":"Small GTP-Binding proteins","volume":"81","author":"Takai","year":"2001","journal-title":"Physiol Rev."},{"issue":"12","key":"B146-20251120","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1111\/1440-1681.12177","article-title":"Aberrant Rac1\u2013mineralocorticoid receptor pathways in salt-sensitive hypertension","volume":"40","author":"Kawarazaki","year":"2013","journal-title":"Clin Exp Pharmacol Physiol."},{"issue":"1","key":"B147-20251120","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000358758","article-title":"Local mineralocorticoid receptor activation and the role of Rac1 in obesity-related diabetic kidney disease","volume":"126","author":"Yoshida","year":"2014","journal-title":"Nephron Exp Nephrol."},{"issue":"1","key":"B148-20251120","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1161\/HYPERTENSIONAHA.121.17263","article-title":"Activation of Rac1-Mineralocorticoid receptor pathway contributes to renal injury in salt-loaded db\/db mice","volume":"78","author":"Hirohama","year":"2021","journal-title":"Hypertension."},{"issue":"3","key":"B149-20251120","doi-asserted-by":"crossref","first-page":"257","DOI":"10.4196\/kjpp.2023.27.3.257","article-title":"Rac1 inhibition protects the kidney against kidney ischemia\/reperfusion through the inhibition of macrophage migration","volume":"27","author":"Park","year":"2023","journal-title":"Korean J Physiol Pharmacol."},{"issue":"4","key":"B150-20251120","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1016\/j.bbrc.2018.07.009","article-title":"Pharmacological inhibition of Rac1 exerts a protective role in ischemia\/reperfusion-induced renal fibrosis","volume":"503","author":"Liang","year":"2018","journal-title":"Biochem Biophysical Res Commun."},{"issue":"12","key":"B151-20251120","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/nm.1879","article-title":"Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease","volume":"14","author":"Shibata","year":"2008","journal-title":"Nat Med."},{"issue":"6","key":"B152-20251120","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1681\/ASN.2011070734","article-title":"Angiotensin II- and salt-induced kidney injury through Rac1-Mediated mineralocorticoid receptor activation","volume":"23","author":"Kawarazaki","year":"2012","journal-title":"J Am Soc Nephrol."},{"issue":"8","key":"B153-20251120","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1172\/JCI43124","article-title":"Rac1 GTPase in rodent kidneys is essential for salt-sensitive hypertension via a mineralocorticoid receptor\u2013dependent pathway","volume":"121","author":"Shibata","year":"2011","journal-title":"J Clin Invest."},{"issue":"11","key":"B154-20251120","doi-asserted-by":"crossref","first-page":"e80328","DOI":"10.1371\/journal.pone.0080328","article-title":"Activation of Rac-1 and RhoA contributes to podocyte injury in chronic kidney disease","volume":"8","author":"Babelova","year":"2013","journal-title":"PLoS One."},{"issue":"1","key":"B155-20251120","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1093\/cvr\/cvac019","article-title":"Renin, aldosterone, the aldosterone-to-renin ratio, and incident hypertension among normotensive subjects from the general population","volume":"119","author":"Arnold","year":"2023","journal-title":"Cardiovasc Res."},{"key":"B156-20251120","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.steroids.2014.08.016","article-title":"Effects of aldosterone on insulin sensitivity and secretion","volume":"91","author":"Luther","year":"2014","journal-title":"Steroids."},{"issue":"1","key":"B157-20251120","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1055\/s-2008-1073128","article-title":"Increased aldosterone levels in a model of type 2 diabetes mellitus","volume":"117","author":"Fredersdorf","year":"2009","journal-title":"Exp Clin Endocrinol Diabetes."},{"issue":"11","key":"B158-20251120","doi-asserted-by":"crossref","first-page":"4472","DOI":"10.1210\/jc.2007-1088","article-title":"Body mass index predicts aldosterone production in normotensive adults on a high-salt diet","volume":"92","author":"Bentley-Lewis","year":"2007","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"B159-20251120","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1161\/HYPERTENSIONAHA.117.10391","article-title":"Aging and adrenal aldosterone production","volume":"71","author":"Nanba","year":"2018","journal-title":"Hypertension."},{"issue":"1","key":"B160-20251120","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/prd.12126","article-title":"The aging population: demographics and the biology of aging","volume":"72","author":"Kanasi","year":"2016","journal-title":"Periodontol 2000."},{"issue":"10027","key":"B161-20251120","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S0140-6736(16)00618-8","article-title":"Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4\u00b74 million participants","volume":"387","year":"2016","journal-title":"Lancet."},{"key":"B162-20251120","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.metabol.2018.09.005","article-title":"The epidemiology of obesity","volume":"92","author":"Chooi","year":"2019","journal-title":"Metabolism."},{"issue":"3","key":"B163-20251120","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1161\/HYPERTENSIONAHA.118.11568","article-title":"Renal outcomes in medically and surgically treated primary aldosteronism","volume":"72","author":"Hundemer","year":"2018","journal-title":"Hypertension."},{"issue":"9","key":"B164-20251120","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1097\/HJH.0b013e3283495cbb","article-title":"Primary aldosteronism: changes in cystatin C-based kidney filtration, proteinuria, and renal duplex indices with treatment","volume":"29","author":"Wu","year":"2011","journal-title":"J Hypertens."},{"issue":"2","key":"B165-20251120","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000345243","article-title":"Vascular actions of aldosterone","volume":"50","author":"Briet","year":"2013","journal-title":"J Vasc Res."},{"issue":"3","key":"B166-20251120","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1161\/HYPERTENSIONAHA.110.165076","article-title":"GPR30, mineralocorticoid receptors, and the rapid vascular effects of aldosterone","volume":"57","author":"Funder","year":"2011","journal-title":"Hypertension."},{"issue":"1","key":"B167-20251120","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.bbrc.2004.04.026","article-title":"Mineralocorticoid receptor antagonists do not block rapid ERK activation by aldosterone","volume":"318","author":"Rossol-Haseroth","year":"2004","journal-title":"Biochem Biophys Res Commun."},{"issue":"8","key":"B168-20251120","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nrneph.2013.110","article-title":"Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis","volume":"9","author":"Brown","year":"2013","journal-title":"Nat Rev Nephrol."},{"issue":"6","key":"B169-20251120","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1161\/CIRCULATIONAHA.123.066314","article-title":"Aldosterone synthase inhibitors and mineralocorticoid receptor antagonists: competitors or collaborators?","volume":"149","author":"Pitt","year":"2024","journal-title":"Circulation."},{"issue":"12","key":"B170-20251120","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.4158\/EP-2020-0277","article-title":"Mineralocorticoid receptor antagonists decrease the rates of positive screening for primary aldosteronism","volume":"26","author":"Tezuka","year":"2020","journal-title":"Endocr Pract."},{"issue":"2","key":"B171-20251120","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.kint.2019.02.030","article-title":"Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis","volume":"96","author":"Barrera-Chimal","year":"2019","journal-title":"Kidney Int."},{"issue":"9","key":"B172-20251120","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1093\/ndt\/gfg265","article-title":"Non-genomic actions of aldosterone: mechanisms and consequences in kidney cells","volume":"18","author":"Boldyreff","year":"2003","journal-title":"Nephrol Dial Transplant."},{"issue":"3","key":"B173-20251120","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1161\/HYPERTENSIONAHA.110.161653","article-title":"GPR30 expression is required for the mineralocorticoid receptor\u2013independent rapid vascular effects of aldosterone","volume":"57","author":"Gros","year":"2011","journal-title":"Hypertension."},{"issue":"1","key":"B174-20251120","doi-asserted-by":"crossref","first-page":"107","DOI":"10.33590\/emjdiabet\/10311665","article-title":"Implication of the MAPK signalling pathway in the pathogenesis of diabetic nephropathy","volume":"7","author":"Barletto Sousa Barros","year":"2019","journal-title":"EMJ Diabet."},{"issue":"1","key":"B175-20251120","first-page":"768512","article-title":"Erk in kidney diseases","volume":"2011","author":"Feliers","year":"2011","journal-title":"J Signal Transduct."},{"issue":"2","key":"B176-20251120","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1046\/j.1523-1755.2001.060002495.x","article-title":"Activation of renal signaling pathways in db\/db mice with type 2 diabetes","volume":"60","author":"Feliers","year":"2001","journal-title":"Kidney Int."},{"issue":"2","key":"B177-20251120","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1523-1755.2005.67102.x","article-title":"MEK inhibitor, U0126, attenuates cisplatin-induced renal injury by decreasing inflammation and apoptosis","volume":"67","author":"Jo","year":"2005","journal-title":"Kidney Int."},{"key":"B178-20251120","doi-asserted-by":"crossref","first-page":"109741","DOI":"10.1016\/j.biopha.2019.109741","article-title":"Interleukin-17A induces renal fibrosis through the ERK and Smad signaling pathways","volume":"123","author":"Weng","year":"2020","journal-title":"Biomed Pharmacother."},{"issue":"12","key":"B179-20251120","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1681\/ASN.V11122222","article-title":"Extracellular signal-regulated kinase mediates stimulation of TGF-beta1 and matrix by high glucose in mesangial cells","volume":"11","author":"Isono","year":"2000","journal-title":"J Am Soc Nephrol."},{"issue":"1","key":"B180-20251120","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1186\/s12964-023-01394-9","article-title":"Targeting Src homology phosphatase 2 ameliorates mouse diabetic nephropathy by attenuating ERK\/NF-\u03baB pathway-mediated renal inflammation","volume":"21","author":"Yu","year":"2023","journal-title":"Cell Commun Signal."},{"issue":"2","key":"B181-20251120","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1080\/10641963.2020.1833022","article-title":"Renal sympathetic denervation attenuates left ventricle hypertrophy in spontaneously hypertensive rats by suppressing the Raf\/MEK\/ERK signaling pathway","volume":"43","author":"Xiao","year":"2021","journal-title":"Clin Exp Hypertens."},{"issue":"6","key":"B182-20251120","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1161\/01.RES.0000159937.05502.d1","article-title":"Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells","volume":"96","author":"Jaffe","year":"2005","journal-title":"Circ Res."},{"issue":"9","key":"B183-20251120","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1161\/CIRCRESAHA.109.196576","article-title":"Aldosterone-induced activation of signaling pathways requires activity of angiotensin type 1a receptors","volume":"105","author":"Lemari\u00e9","year":"2009","journal-title":"Circ Res."},{"issue":"12","key":"B184-20251120","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1139\/y85-250","article-title":"Effect of aldosterone on vascular angiotensin II receptors in the rat","volume":"63","author":"Schiffrin","year":"1985","journal-title":"Can J Physiol Pharmacol."},{"issue":"5","key":"B185-20251120","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1161\/HYPERTENSIONAHA.115.07074","article-title":"Aldosterone-induced vascular remodeling and endothelial dysfunction require functional angiotensin type 1a receptors","volume":"67","author":"Briet","year":"2016","journal-title":"Hypertension."},{"issue":"18","key":"B186-20251120","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1161\/CIRCULATIONAHA.111.029892","article-title":"Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial","volume":"124","author":"Calhoun","year":"2011","journal-title":"Circulation."},{"issue":"5","key":"B187-20251120","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1007\/s11906-013-0379-7","article-title":"Aldosterone synthase inhibition in hypertension","volume":"15","author":"Andersen","year":"2013","journal-title":"Curr Hypertens Rep."},{"issue":"3","key":"B188-20251120","doi-asserted-by":"crossref","first-page":"H670","DOI":"10.1152\/ajpheart.00419.2023","article-title":"Aldosterone and aldosterone synthase inhibitors in cardiorenal disease","volume":"326","author":"Verma","year":"2024","journal-title":"Am J Physiol Heart Circ Physiol."},{"key":"B189-20251120","doi-asserted-by":"crossref","first-page":"1423027","DOI":"10.3389\/fendo.2024.1423027","article-title":"Evaluating the role of aldosterone synthesis on adrenal cell fate","volume":"15","author":"Aminuddin","year":"2024","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"6","key":"B190-20251120","doi-asserted-by":"crossref","first-page":"5782","DOI":"10.3390\/ijms24065782","article-title":"Molecular and epigenetic control of aldosterone synthase, CYP11B2 and 11-Hydroxylase, CYP11B1","volume":"24","author":"Takeda","year":"2023","journal-title":"Int J Mol Sci."},{"issue":"5","key":"B191-20251120","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1161\/HYPERTENSIONAHA.110.157271","article-title":"Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism","volume":"56","author":"Amar","year":"2010","journal-title":"Hypertension."},{"issue":"5","key":"B192-20251120","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa2213169","article-title":"Phase 2 trial of baxdrostat for treatment-resistant hypertension","volume":"388","author":"Freeman","year":"2023","journal-title":"New Engl J Med."},{"issue":"12","key":"B193-20251120","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1001\/jama.2023.16029","article-title":"Aldosterone synthase inhibition with lorundrostat for uncontrolled hypertension: the Target-HTN randomized clinical trial","volume":"330","author":"Laffin","year":"2023","journal-title":"JAMA."},{"issue":"18","key":"B194-20251120","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2501440","article-title":"Lorundrostat efficacy and safety in patients with uncontrolled hypertension","volume":"392","author":"Laffin","year":"2025","journal-title":"New Engl J Med."},{"issue":"8","key":"B195-20251120","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S0735-1097(23)00750-7","article-title":"Highly effective blood pressure lowering with mls-101, a new aldosterone synthase inhibitor, in individuals with obesity and raas dysregulation","volume":"81","author":"Rodman","year":"2023","journal-title":"J Am Coll Cardiol."},{"issue":"3","key":"B196-20251120","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/jch.12051","article-title":"Study of aldosterone synthase inhibition as an add-on therapy in resistant hypertension","volume":"15","author":"Karns","year":"2013","journal-title":"J Clin Hypertens (Greenwich)."},{"issue":"22","key":"B197-20251120","doi-asserted-by":"crossref","first-page":"13749","DOI":"10.3390\/ijms232213749","article-title":"Sodium-glucose cotransporter-2 inhibitors-miracle drugs for the treatment of chronic kidney disease irrespective of the diabetes status: lessons from the dedicated kidney disease-focused CREDENCE and DAPA-CKD trials","volume":"23","author":"Gohda","year":"2022","journal-title":"Int J Mol Sci."},{"issue":"2","key":"B198-20251120","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3390\/biomedicines11020279","article-title":"SGLT2 inhibitors in diabetic and non-diabetic chronic kidney disease","volume":"11","author":"Podest\u00e0","year":"2023","journal-title":"Biomedicines."},{"key":"B199-20251120","doi-asserted-by":"crossref","first-page":"108368","DOI":"10.1016\/j.diabres.2020.108368","article-title":"A systematic review examining the effects of sodium-glucose cotransporter-2 inhibitors (SGLT2is) on biomarkers of inflammation and oxidative stress","volume":"168","author":"Bray","year":"2020","journal-title":"Diabetes Res Clin Pract."},{"key":"B200-20251120","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3389\/fcvm.2016.00043","article-title":"Glycemic control with ipragliflozin, a novel selective SGLT2 inhibitor, ameliorated endothelial dysfunction in streptozotocin-induced diabetic mouse","volume":"3","author":"Salim","year":"2016","journal-title":"Front Cardiovasc Med."},{"issue":"1-3","key":"B201-20251120","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ejphar.2013.05.014","article-title":"Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice","volume":"715","author":"Tahara","year":"2013","journal-title":"Eur J Pharmacol."},{"key":"B202-20251120","doi-asserted-by":"crossref","first-page":"154334","DOI":"10.1016\/j.metabol.2020.154334","article-title":"Empagliflozin improves diabetic renal tubular injury by alleviating mitochondrial fission via AMPK\/SP1\/PGAM5 pathway","volume":"111","author":"Liu","year":"2020","journal-title":"Metabolism."},{"issue":"1","key":"B203-20251120","doi-asserted-by":"crossref","first-page":"e22078","DOI":"10.1096\/fj.202100909RR","article-title":"SGLT2 inhibitor counteracts NLRP3 inflammasome via tubular metabolite itaconate in fibrosis kidney","volume":"36","author":"Ke","year":"2022","journal-title":"FASEB J."},{"issue":"3","key":"B204-20251120","doi-asserted-by":"crossref","first-page":"F317","DOI":"10.1152\/ajprenal.00145.2014","article-title":"The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob\/ob type 2 diabetic mice with and without hypertension","volume":"307","author":"Gembardt","year":"2014","journal-title":"Am J Physiol Renal Physiol."},{"issue":"6","key":"B205-20251120","doi-asserted-by":"crossref","first-page":"e129034","DOI":"10.1172\/jci.insight.129034","article-title":"Renal protective effects of empagliflozin via inhibition of EMT and aberrant glycolysis in proximal tubules","volume":"5","author":"Li","year":"2020","journal-title":"JCI Insight."},{"key":"B206-20251120","doi-asserted-by":"crossref","first-page":"113947","DOI":"10.1016\/j.biopha.2022.113947","article-title":"Empagliflozin reduces kidney fibrosis and improves kidney function by alternative macrophage activation in rats with 5\/6-nephrectomy","volume":"156","author":"Lu","year":"2022","journal-title":"Biomed Pharmacother."},{"key":"B207-20251120","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.bbrc.2023.01.084","article-title":"Canagliflozin ameliorates epithelial-mesenchymal transition in high-salt diet-induced hypertensive renal injury through restoration of sirtuin 3 expression and the reduction of oxidative stress","volume":"653","author":"Wang","year":"2023","journal-title":"Biochem Biophysical Res Commun."},{"issue":"8","key":"B208-20251120","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1159\/000516213","article-title":"Effects of finerenone combined with empagliflozin in a model of hypertension-induced end-organ damage","volume":"52","author":"Kolkhof","year":"2021","journal-title":"Am J Nephrol."},{"issue":"1","key":"B209-20251120","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ekir.2021.10.008","article-title":"Finerenone in predominantly advanced CKD and type 2 diabetes with or without sodium-glucose Cotransporter-2 inhibitor therapy","volume":"7","author":"Rossing","year":"2022","journal-title":"Kidney Int Rep."},{"issue":"2","key":"B210-20251120","first-page":"236","article-title":"Mineralocorticoid receptor antagonist combined with SGLT2 inhibitor versus SGLT2 inhibitor alone in chronic kidney disease: a meta-analysis of randomized trials","volume":"56","author":"Ferreira","year":"2025","journal-title":"Am J Nephrol."},{"key":"B211-20251120","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2410659","article-title":"Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes","author":"Agarwal","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"B212-20251120","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1681\/ASN.2021070942","article-title":"Hyperkalemia risk with finerenone: results from the FIDELIO-DKD trial","volume":"33","author":"Agarwal","year":"2022","journal-title":"J Am Soc Nephrol."},{"issue":"48","key":"B213-20251120","doi-asserted-by":"crossref","first-page":"4891","DOI":"10.1093\/eurheartj\/ehab497","article-title":"Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial","volume":"42","author":"Neuen","year":"2021","journal-title":"Eur Heart J."}],"container-title":["Kidney360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000000929","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:03:37Z","timestamp":1786478617000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000000929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":213,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.34067\/kid.0000000929","relation":{},"ISSN":["2641-7650"],"issn-type":[{"value":"2641-7650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,22]]}}}